Galantamine in the treatment of moderate-to-advanced Alzheimer's patients: Clinical outcomes in assisted living

被引：0
|
作者：
Shua-Haim, J
Pass, M
Patel, S
Patel, S
机构：
来源：
GERONTOLOGIST | 2003年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学]; R592 [老年病学];
学科分类号：
1002 ; 100203 ; 100602 ;
摘要：
引用
收藏
页码：433 / 433
页数：1
相关论文
共 50 条
  • [1] Galantamine in the treatment of moderate-to-advanced Alzheimer's patients: Clinical and pharmacoeconomic outcomes in assisted living
    Shua-Haim, JR
    Pass, M
    Patel, S
    Patel, S
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 316 - 316
  • [2] Galantamine in the treatment of moderate to advanced Alzheimer's disease: Clinical and pharmacoeconomic outcomes in the assisted living environment
    Shua-Haim, JR
    Pass, MD
    Patel, S
    Patel, S
    Smith, J
    NEUROBIOLOGY OF AGING, 2004, 25 : S184 - S184
  • [3] Efficacy and tolerability of galantamine in the treatment of patients with mild to moderate Alzheimer's disease in the routine clinical practice
    Kogoj, A.
    Denislic, M.
    Ambrozic, D.
    Hren, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 190 - 190
  • [4] The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer's Disease
    Ohnishi, Takashi
    Sakiyama, Yojiro
    Okuri, Yuichi
    Kimura, Yuji
    Sugiyama, Nami
    Saito, Takayuki
    Takahashi, Masayoshi
    Kobayashi, Takumi
    CURRENT ALZHEIMER RESEARCH, 2014, 11 (02) : 110 - 118
  • [5] Switching, strategy with galantamine in the treatment of patients with mild to moderate Alzheimer's disease
    Hwang, T-Y.
    Ahn, I-S.
    Yun, J.
    Kim, S.
    Kim, D. K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 172 - 172
  • [6] Galantamine has beneficial effects on aggression and agitation in patients with advanced moderate Alzheimer's disease
    Kurz, A
    Schwalen, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S120 - S121
  • [7] The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer's Disease
    Lee, Jae-Hong
    Hong, Yun Jeong
    Bae, Hee-Joon
    Kim, Beom Joon
    Na, Duk-Lyul
    Han, Seol-Heui
    Park, Jong-Moo
    Jeong, Jee-Hyang
    Cha, Kyung-Ryeol
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 66 - 72
  • [8] Galantamine significantly improves all aspects of cognition in patients with 'advanced-moderate' Alzheimer's disease
    Blesa, R
    Schwalen, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S76 - S76
  • [9] The long-term benefits of galantamine in "advanced-moderate" Alzheimer's disease patients.
    Blesa, R
    Reichman, W
    Schwalen, S
    Kershaw, P
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S81 - S82
  • [10] Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months
    Blesa, R
    Davidson, M
    Kurz, A
    Reichman, W
    van Baelen, B
    Schwalen, S
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (02) : 79 - 87
12345